Encapsulation of the Antistaphylococcal Endolysin LysRODI in pH-Sensitive Liposomes

© 2020 by the authors.Phage lysins are promising new therapeutics against multidrug-resistant bacteria. These so-called enzybiotics offer, amongst their most notable advantages, high target specificity and low resistance development. Moreover, there are numerous recent and ongoing studies aimed at demonstrating the efficacy and safety of endolysins in animal models or even in clinical trials. Nonetheless, as is the case for other antimicrobials, it is important to assess potential strategies that may broaden their potential applications or improve their stability. Encapsulation, for instance, has given very good results for some antibiotics. This study sought to evaluate the feasibility of encapsulating an endolysin against the opportunistic human pathogen Staphylococcus aureus, one of the most problematic bacteria in the context of the current antibiotic resistance crisis. Endolysin LysRODI has antimicrobial activity against many S. aureus strains from different sources, including methicillin-resistant S. aureus (MRSA) isolates. Here, this protein was encapsulated in pH-sensitive liposomes with an efficacy of approximately 47%, retaining its activity after being released from the nanocapsules. Additionally, the encapsulated endolysin effectively reduced S. aureus cell counts by > 2log units in both planktonic cultures and biofilms upon incubation at pH 5. These results demonstrate the viability of LysRODI encapsulation in liposomes for its targeted delivery under mild acidic conditionsThis study was funded by grants AGL2015-65673-R (MINECO/FEDER, UE), EU ANIWHA ERA-NET (BLAAT ID: 67)/PCIN-2017-001 (AEI/FEDER, UE), Proyecto Intramural CSIC201670E040, Proyecto Intramural CSIC 201770E016. IDI/2018/000119 (Program of Science, Technology and Innovation 2018-2020 and FEDER EU funds, Principado de Asturias, Spain). S.P. has a postdoctoral fellowship CONACYT (México)Peer reviewe